The narrower loss and extended cash runway reduce near-term dilution risk, but the stock remains binary on clinical data. Key catalysts: GLP-131 28-day weight data in Q2 2026 and COVALENT-211/212 26-week T2D data in Q4 2026. Monitor cash burn trajectory — at current rate, a financing event may be needed by early 2027 if no partnership or milestone payments materialize.
Price Chart
Executive Summary
Biomea Fusion reported Q1 2026 net loss of $12.4M ($0.17/share), significantly narrower than the $29.3M loss in Q1 2025, driven by a 60% reduction in R&D spending. The company highlighted positive Phase II data for icovamenib in type 1 diabetes and initiated two Phase II trials in type 2 diabetes, with topline data expected in Q4 2026. Cash runway extends into Q1 2027, providing a 9-month operational buffer.
Key Financial Metrics
Key Facts
- Net loss narrowed to $12.4M from $29.3M YoY, beating consensus EPS of -$0.19 with actual -$0.17
- Cash and equivalents at $45.1M, projected runway into Q1 2027
- Phase II COVALENT-112 T1D trial showed 52% C-peptide increase at Week 12, sustained through Week 52
- Two Phase II T2D trials (COVALENT-211 and -212) initiated, topline 26-week data expected Q4 2026
- Phase I GLP-131 obesity trial ongoing, initial 28-day weight data expected Q2 2026
- R&D expenses fell 60% YoY to $9.1M due to reduced clinical and personnel costs
- Stock-based compensation halved to $1.6M
Financial Impact
Net loss improved 58% YoY to $12.4M; cash burn rate ~$3.7M/month based on $11.1M quarterly decrease in cash
Risk Factors
- Clinical trial failure risk — icovamenib and BMF-650 are unapproved, early-stage assets
- Cash runway only into Q1 2027 — likely requires additional financing before data readouts
- Low trading liquidity and $111M market cap amplify volatility on any news
- Historical EPS misses (Dec 2025: -$0.64 vs -$0.25 consensus) show execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292393 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6230 (−25.30%) |
Oct 13, 2026 13d ago | Press Release | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6230 (−25.30%) |
Sep 23, 2026 4w ago | Press Release | $1.44 $1.33 | ▼ −7.64% | ▼ −6.96% | $0.6230 (−56.74%) |
Sep 22, 2026 4w ago | 424B5 | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6230 (+56.74%) |
Sep 22, 2026 4w ago | Press Release | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6230 (+56.74%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.17 $1.18 | ▲ +0.85% | ▲ +0.18% | $0.6230 (−46.75%) |
Jun 5, 2026 20w ago | Press Release | $1.15 $1.20 | ▲ +4.35% | ▲ +2.24% | $0.6230 (−45.83%) |
May 11, 2026 24w ago | 8-K | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6230 (−60.57%) |
May 11, 2026 24w ago | Press Release | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6230 (−60.57%) |
Apr 28, 2026 26w ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $0.6230 (−59.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers